Frazier Life Sciences Appoints Christian Schade as Senior Advisor

Key Terms

nasdaq financial

The Nasdaq is a stock exchange where many companies' shares are bought and sold, functioning much like a marketplace for investments. It matters to investors because it provides a platform to buy and sell ownership stakes in companies, helping them track the value of those companies and make informed decisions. As one of the largest and most technology-focused markets, it also reflects trends and developments in the business world.

ipo financial

An initial public offering (IPO) is the process by which a private company sells its shares to the public for the first time, making its ownership available on the stock market. This allows the company to raise money from a wide range of investors to fund growth or other goals. For investors, an IPO offers a chance to buy into a company early in its public journey, potentially benefiting if the company grows in value.

dyslipidemia medical

Dyslipidemia is a medical condition where the levels of fats in the blood—such as cholesterol and triglycerides—are outside the healthy range, increasing the risk of artery blockages and heart disease; think of it as having oily buildup in plumbing that can slow or clog flow. It matters to investors because it drives demand for drugs, medical devices and diagnostics, influences healthcare costs and insurance payouts, and can affect the commercial and regulatory prospects of companies developing treatments.

PALO ALTO, Calif.--(BUSINESS WIRE)-- Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointment of Christian Schade as Senior Advisor. Chris will join FLS’ Boston office and work closely with the firm’s portfolio companies on corporate strategy and business development.

“Chris brings deep operational and financial experience with both private and public biopharma companies,” said Joe Cabral, Partner at Frazier Life Sciences. “His leadership experience and ability to guide companies through critical inflection points make him a strong addition to our advisory team. We’re pleased to welcome him as we continue building out our Boston team.”

Mr. Schade joins Frazier Life Sciences with more than 30 years of experience in the pharmaceutical and biotechnology industries. Most recently, he served as President and Chief Executive Officer of Halda Therapeutics, a company developing a novel class of cancer therapies, where he led the organization through its acquisition by Johnson & Johnson in December 2025.

“The Frazier Life Sciences team has a strong history of supporting companies at pivotal moments in their evolution, and I look forward to working with founders and leaders as they work to translate scientific discoveries into potentially groundbreaking therapies for the benefit of patients in need,” said Chris Schade.

Prior to his role at Halda, Mr. Schade served as President, Chief Executive Officer and Board Member of Aprea Therapeutics (Nasdaq: APRE) from 2016 to 2022, and as Chairman from 2020 to 2023. Under his leadership, Aprea advanced its pipeline of oncology therapeutics and completed its IPO in 2019. Before joining Aprea, he held several executive roles at biotechnology companies developing emerging therapeutics, including: Chief Executive Officer of Novira, a privately held antiviral drug discovery company until its acquisition by Johnson & Johnson, Chief Financial Officer of Omthera Pharmaceuticals, Inc., a Nasdaq-listed specialty pharmaceuticals company focused on new therapies for dyslipidemia until its acquisition by AstraZeneca Plc, and Senior Vice President of Administration and Chief Financial Officer at Medarex, Inc., a biopharmaceutical company focused on antibody-based therapeutic products for oncology, inflammation, autoimmune disorders and infectious diseases until its acquisition by Bristol-Myers Squibb.

Earlier in his career, Mr. Schade was Managing Director at Merrill Lynch in London, following nearly 20 years in corporate finance and capital markets roles at Merrill Lynch and JPMorgan in New York and London.

Chris received his A.B. degree from Princeton University and an M.B.A. from the Wharton School at the University of Pennsylvania.

About Frazier Life Sciences:

Frazier Life Sciences (FLS) invests globally in private and publicly traded companies that discover, develop, and commercialize innovative biopharmaceuticals. The firm manages over $5 billion in capital across venture and public strategies. Since 2010, FLS portfolio companies have achieved 76 FDA-approved therapeutics and completed more than 60 IPOs or strategic acquisitions.

FLS is headquartered in Palo Alto, CA, with offices in San Diego, Seattle and Boston.

For more information about FLS, please visit frazierls.com and follow us on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260406901809/en/

For media inquiries, please contact:

Frazier Life Sciences

Investor Relations

ir@frazierls.com

Source: Frazier Life Sciences